Next Article in Journal
Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort
Next Article in Special Issue
Low Numbers of Vascular Vessels Correlate to Progression in Hormone-Naïve Prostate Carcinomas Undergoing Radical Prostatectomy
Previous Article in Journal
Radiotherapy-Induced Changes in the Systemic Immune and Inflammation Parameters of Head and Neck Cancer Patients
Previous Article in Special Issue
Neuromedin U: A Small Peptide in the Big World of Cancer
Open AccessReview

Panoptic View of Prognostic Models for Personalized Breast Cancer Management

Department of Biology, Georgia State University, Atlanta, GA 30303, USA
Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway
Department of Hematology and Medical Oncology, Emory University School of Medicine; Atlanta, GA 30322, USA
Author to whom correspondence should be addressed.
Cancers 2019, 11(9), 1325;
Received: 5 August 2019 / Revised: 3 September 2019 / Accepted: 5 September 2019 / Published: 7 September 2019
(This article belongs to the Special Issue New Biomarkers in Cancers)
The efforts to personalize treatment for patients with breast cancer have led to a focus on the deeper characterization of genotypic and phenotypic heterogeneity among breast cancers. Traditional pathology utilizes microscopy to profile the morphologic features and organizational architecture of tumor tissue for predicting the course of disease, and is the first-line set of guiding tools for customizing treatment decision-making. Currently, clinicians use this information, combined with the disease stage, to predict patient prognosis to some extent. However, tumoral heterogeneity stubbornly persists among patient subgroups delineated by these clinicopathologic characteristics, as currently used methodologies in diagnostic pathology lack the capability to discern deeper genotypic and subtler phenotypic differences among individual patients. Recent advancements in molecular pathology, however, are poised to change this by joining forces with multiple-omics technologies (genomics, transcriptomics, epigenomics, proteomics, and metabolomics) that provide a wealth of data about the precise molecular complement of each patient’s tumor. In addition, these technologies inform the drivers of disease aggressiveness, the determinants of therapeutic response, and new treatment targets in the individual patient. The tumor architecture information can be integrated with the knowledge of the detailed mutational, transcriptional, and proteomic phenotypes of cancer cells within individual tumors to derive a new level of biologic insight that enables powerful, data-driven patient stratification and customization of treatment for each patient, at each stage of the disease. This review summarizes the prognostic and predictive insights provided by commercially available gene expression-based tests and other multivariate or clinical -omics-based prognostic/predictive models currently under development, and proposes a more inclusive multiplatform approach to tackling the challenging heterogeneity of breast cancer to individualize its management. “The future is already here—it’s just not very evenly distributed.”-William Ford Gibson View Full-Text
Keywords: breast cancer; prognosis; prediction; liquid biopsy; immunohistochemistry; digital pathology; multigene assays breast cancer; prognosis; prediction; liquid biopsy; immunohistochemistry; digital pathology; multigene assays
Show Figures

Figure 1

MDPI and ACS Style

Saini, G.; Mittal, K.; Rida, P.; Janssen, E.A.M.; Gogineni, K.; Aneja, R. Panoptic View of Prognostic Models for Personalized Breast Cancer Management. Cancers 2019, 11, 1325.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop